FDA approves combination therapy Juvisync

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and...

FDA announces changes in drug center’s oncology office

Today, the U.S. Food and Drug Administration announced organizational changes within the office responsible for reviewing all drug and biologic applications for cancer therapies. ivermectin for horses The Center for Drug Evaluation and Research’s (CDER) Office of...